Clinical trial · Observational
Annexin A2 as a Novel Diagnostic Marker in Hepatocellular Carcinoma
Evaluation of Annexin A2 as a Novel Diagnostic Marker for Hepatocellular Carcinoma in Egyptian Patients
NCT02541149CI-TRIAL-00019047completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study aimed to investigate the clinical utility of Annexin A2 serum level as a novel diagnostic marker of hepatocellular carcinoma (HCC) and to correlate its level with alpha fetoprotein the current marker ofhepatocellular carcinoma (HCC).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocellular Carcinoma (HCC) | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.85 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| blood sample | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- label
- Group 1:
- description
- Fifty patients with early stage hepatocellular carcinoma(BCLC stage A)
- interventionNames
- Procedure: blood sample
- label
- Group 2
- description
- Twenty five patients with chronic liver disease diagnosed based on clinical, laboratory, and ultrasonographic investigations;
- interventionNames
- Procedure: blood sample
- label
- Group 3
- description
- Control Group: Fifteen healthy, age and sex-matched subjects with seronegative hepatitis viral markers
- interventionNames
- Procedure: blood sample
Primary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * Inclusion criteria for HCC cases: 1. Confirmed diagnosis of HCC according to the European association of study of liver diseases \[13\]. 2. Early stage HCC (Stage A), using the Barcelona Clinic Liver Cancer (BCLC) staging system, (single or 3 nodules \< 3cm PS 0) For all participants:. * Informed consent from all participants before enrollment in the study. Exclusion Criteria: * For HCC patients: 1-Imtermediate or advanced stage HCC as defined by BCLC 2. Major vascular tumor invasion or metastasis confirmed by radiological imaging studies. 3\. Patients with other suspected solid malignancies or metastatic liver tumors, 4. Other types of chronic liver diseases (CLD) such as autoimmune hepatitis and primary biliary cirrhosis. * For all participants: * Refusal to participate in the study
References
Publications (0)
Data not yet available
No reference posted for this study.